There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TGF-Beta 2

TGF-Beta 2

Brief Information

Name:Transforming growth factor beta 2
Target Synonym:Prepro-Transforming Growth Factor Beta-2,Cetermin,Glioblastoma-Derived T-Cell Suppressor Factor,Polyergin,TGF-beta-2,BSC-1 Cell Growth Inhibitor,Transforming Growth Factor Beta 2,Transforming Growth Factor, Beta 2,TGFB2,LDS4,Transforming Growth Factor Bet
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
TG2-H8212 Human Biotinylated Human TGF-Beta 2 / TGFB2 Protein, Avitag™
TG2-H4215 Human Human TGF-Beta 2 / TGFB2 Protein, Tag Free

Part of Bioactivity data


Loaded Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) on Protein A Biosensor, can bind Human TGF-Beta 2, Tag Free (Cat. No. TG2-H4215) with an affinity constant of 8.09 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Synonym Name



Transforming growth factor beta 2 ( TGFB2) is also known as TGF-β2, G-TSF, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB2 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB2 protein can inhibit the T cell growth by IL-2-dependent. and can inhibit immune surveillance during tumor development, the protein promoting tumor growth with an autocrine manner. TGF-β2 can affect the viability of killer cells and reduce the expression of IL-2, IL-6, IL-10, IFN-γ and other cytokines.TGFB2 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ENERGI-F701 ENERGI-F701 Phase 2 Clinical Energenesis Biomedical Alopecia Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.